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ABSTRACT: Plasmid-based genetic systems in Escherichia coli are
a staple of synthetic biology. However, the use of plasmids imposes
limitations on the size of synthetic gene circuits and the ease with
which they can be placed into bacterial hosts. For instance, unique
selective markers must be used for each plasmid to ensure their
maintenance in the host. These selective markers are most often
genes encoding resistance to antibiotics such as ampicillin or
kanamycin. However, the simultaneous use of multiple antibiotics to
retain diﬀerent plasmids can place undue stress on the host and
increase the cost of growth media. To address this problem, we have developed a method for stably transforming three diﬀerent
plasmids in E. coli using a single antibiotic selective marker. To do this, we ﬁrst examined two diﬀerent systems with which two
plasmids may be maintained. These systems make use of either T7 RNA polymerase-speciﬁc regulation of the resistance gene or
split antibiotic resistance enzymes encoded on separate plasmids. Finally, we combined the two methods to create a system with
which three plasmids can be transformed and stably maintained using a single selective marker. This work shows that large-scale
plasmid-based synthetic gene circuits need not be limited by the use of multiple antibiotic resistance genes.
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The creation of synthetic gene circuits in Escherichia coli ismost often done with the use of plasmids. The ease with
which plasmids can be transformed into E. coli and the many
tools that are available for manipulating their DNA sequences
make them a robust platform for designing, testing and
implementing regulatory architectures. Indeed, many previously
reported synthetic gene circuits have been constructed on
plasmids, including toggle switches,1,13 gene oscillators,2,11,21
light-sensitive networks17,23 and logic gates.24 However, as the
size and complexity of synthetic gene circuits increase, so too
does the need for plasmid-based frameworks that can
simultaneously maximize the amount of DNA and minimize
the strain on the host.
Plasmid-based synthetic gene circuits frequently use multiple
plasmids to house the necessary DNA. In order to stably
maintain multiple plasmids within the host, each plasmid type
must contain a unique selective marker. For instance, synthetic
gene circuits that use two plasmids often contain one plasmid
that confers resistance to ampicillin and another plasmid
conferring resistance to kanamycin.11,21 While these two
selective markers work well together, there are some
limitations. For instance, long-term cultures of cells containing
ampicillin resistance can spawn cheater cells that have lost the
plasmid containing bla,10 the gene encoding β-lactamase.
Further, the metabolic burden of producing the proteins
necessary to impart resistance to multiple antibiotics can
exhaust cellular resources and slow growth.3,4,7
Currently, there exist several methods for stably maintaining
a single plasmid type without resorting to antibiotics.25 Most of
these methods involve modifying the chromosome of the host.
For instance, one method is to remove an essential gene, such
as infA or glyA, from the chromosome and include it on the
plasmid.14,26 Another method represses the essential gene dapD
by placing it under control of the lac promoter.8 This
repression is then alleviated by transforming in a plasmid
containing lacO sites that compete with the promoter for LacI
occupancy.
In this study we examined methods for stably maintaining
multiple plasmid types using a single selective marker, here the
antibiotic kanamycin. We constructed and characterized three
diﬀerent synthetic gene circuits that confer antibiotic resistance
to the host if and only if multiple plasmids are present. Each
circuit is designed so that no single plasmid can produce
resistance in the absence of the others. These systems can easily
be used in many diﬀerent E. coli strains, provided those strains
contain no source of T7 RNA polymerase (T7RNAP).
The ﬁrst two designs each require two diﬀerent plasmids to
confer kanamycin resistance. In one of these, we used the RNA
polymerase from phage T7 to drive expression of the gene
(neo) encoding aminoglycoside phosphotransferase (3′)-IIa
(NptII), which confers resistance to kanamycin. By placing the
gene encoding T7RNAP on one plasmid, and a T7RNAP
speciﬁc promoter driving neo on the other, both plasmids are
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required for kanamycin resistance. In the other two-plasmid
network, we examined a previously reported split NptII system,
with the genes encoding either half of the enzyme being placed
on two diﬀerent plasmids.19 Finally, we constructed a circuit
that combines the two above systems to create a system that
requires three diﬀerent plasmids. To do this, we replaced the
constitutive promoters driving the two halves of the split neo
gene above with promoters targeted by T7RNAP. Therefore, in
addition to the plasmids containing the two halves of neo, a
third plasmid encoding T7RNAP is required to confer
kanamycin resistance.
We ﬁnd that stable maintenance of multiple plasmids using a
single selective marker (in this case kanamycin) is possible.
Each of the three systems is not only able to confer kanamycin
resistance to the host, but also capable of being maintained
during long-term serial dilution experiments. In addition, we
ﬁnd these systems can be directly transformed into their host
and plated onto media containing only kanamycin. This
capability alleviates the need for ‘‘back-up’’ resistance markers
on each plasmid and thereby reduces the necessary size and
metabolic load of each plasmid.
We ﬁrst designed a scheme (Scheme 1, Figure 1A) in which
one plasmid, pTara, houses the gene encoding T7RNAP driven
by the arabinose-inducible PBAD promoter.
27 In addition, a
second plasmid, pCS1, contains the neo gene driven by a hybrid
PT7/lac promoter. Since T7 promoters are orthogonal to native
E. coli RNA polymerases,22 transcription of the neo gene is
initiated only in the presence of T7RNAP. In addition, the
PT7/lac promoter contains a LacI operator site to allow control
over the amount of transcription through titration of isopropyl
β-D-1-thiogalactopyranoside (IPTG).9 Because transcription of
neo requires both plasmids, host strains will be resistant to
kanamycin only if both plasmids are present.
We found that Scheme 1 could confer resistance to
kanamycin. To test this, cells were transformed with either
the full system (pTara and pCS1) or a partial system (pTara or
pCS1 or neither). The bacteria were streaked onto solid
lysongeny broth (LB) agar plates containing kanamycin and
passed into liquid LB with kanamycin. Cultures were then
allowed to grow overnight. When plated onto media with
kanamycin, as shown in Figure 1B, the full system shows robust
growth. However, we also found that it is susceptible to
mutation. While cells transformed with only pTara or neither
plasmid showed no growth, several colonies were observed with
cells transformed with just pCS1. Similar results were observed
when these strains were grown in liquid cultures (Figure 1C).
Upon sequencing, it was found that cells transformed with
just pCS1 and grown in the presence of kanamycin had
obtained mutations to the T7 promoter driving neo. Speciﬁcally,
we found that an IS10 insertion sequence had been placed into
the promoter. Upon induction of cellular stress, the IS10
sequence is randomly inserted into DNA by Tn10 trans-
posase.12 It is not site speciﬁc, as sequencing showed that the
insertion sequence was not always inserted into the same
position on the plasmid. It was usually inserted into a position
near the beginning of the T7 promoter, presumably disrupting
the orthogonality of the T7 promoter and allowing native E. coli
RNAP to transcribe neo. No similar mutations were ever
noticed when both pTara and pCS1 were transformed together
and relied upon to confer kanamycin resistance, even after 30
days of serial dilution (see below).
The design for Scheme 2 (Figure 1D) utilizes a split version
of neo.19 This split version of neo has an N-terminal fragment
encoding residues 1−59 (neo-α) of NptII and a C-terminal
fragment encoding residues 59−264 (neo-β). In addition, both
halves contain a leucine zipper fusion to promote dimerization
Figure 1. Two circuit designs for stable maintenance of two plasmids. (A) Scheme 1: The ﬁrst plasmid produces T7RNAP, which is required for the
transcription of the neo gene on the second plasmid. (B) Growth on kanamycin plates of cells containing both pTara and pCS1 (top quarter), pTara
(left), pCS1 (right) or neither (bottom). While the full system confers resistance, several colonies (red arrows) arise when just pCS1 is present. (C)
Liquid culture experiments show the pattern as the plating experiments. Shown is a picture of a representative sample of culture tubes containing
cells transformed with the various combinations of the two plasmids (top) and their respective OD600 measurements (below). (D) Scheme 2: The
neo gene is split to produce proteins that are enzymatically active only as a dimer. One plasmid contains the N-terminal portion (neo-α), while the
other plasmid contains the C-terminal portion (neo-β). (E) and (F) Plating and liquid culture experiments similar to (B) and (C). Unlike Scheme 1,
Scheme 2 shows no mutations that confer kanamycin resistance (see text for details). Photographs in (B), (C), (E) and (F) are representative
samples of at least three experiments. Error bars in (C) and (F) are the standard deviations from at least three separate cultures.
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of the two fragments. Neither half of the split NptII is
enzymatically active, but the dimer confers resistance to
kanamycin. Therefore, host strains will survive in the presence
of kanamycin only if both plasmids are present.
Growth experiments with Scheme 2 showed that both
plasmids were required for growth in the presence of
kanamycin, both on plates (Figure 1E) and in liquid (Figure
1F). In addition, no mutations were ever observed allowing
either of the two plasmids, in the absence of the other, to confer
kanamycin resistance to the host.
We next designed a system that requires three plasmids to
confer kanamycin resistance. Scheme 3, shown in Figure 2A,
uses a combination of Schemes 1 and 2. By replacing the
constitutive promoters that drive expression of neo-α and neo-β
from Scheme 2 with the PT7/lac promoter, the system now
requires T7RNAP to be supplied by a third plasmid, as in
Scheme 1.
As with the two-plasmid systems, we tested whether or not
our three-plasmid circuit was necessary and suﬃcient for robust
growth in the presence of kanamycin. We examined the growth
of various strains containing all eight possible combinations of
the three plasmids. When grown on plates (Figure 2B) or in
liquid media (Figure 2C), we found that only those cells
containing the full system grew.
Interestingly, unlike Scheme 1, which also relies on
T7RNAP, the three-plasmid system did not show susceptibility
to mutation while lacking one or more of the plasmids. In
particular, since cells lacking T7RNAP in the two-plasmid
system were able to mutate and grow in kanamycin, we were
concerned that the three-plasmid system had a similar
vulnerability. When cells transformed with the two plasmids
containing neo-α and neo-β driven by the T7 promoter (pCS4
and pCS5) were grown in the presence of kanamycin, no
mutations were ever observed that conferred resistance. This is
perhaps due to the split nature of the resistance gene and the
fact that transposon insertion is a rare event. In other words,
while the neo containing plasmid from Scheme 1 (pCS1) only
requires a single insertion event, pCS4 and pCS5 require two
such events to occur nearly simultaneously to confer resistance
in the absence of T7RNAP.
Each plasmid of the three schemes described above
contained a ‘‘backup’’ antibiotic marker. These backup
resistance genes aided in cloning each plasmid and allowed
us to ﬁrst transform them into strains before testing the eﬃcacy
of kanamycin resistance. However, we wanted to test whether
or not these backup resistance markers were essential and if the
schemes could be plated directly onto kanamycin plates after
transformation.
We found that each system could be transformed into
competent cells and plated directly onto kanamycin plates.
However, the transformation eﬃciency of each system was
signiﬁcantly less when plated onto kanamycin than when plated
onto the back-up antibiotics, as shown in Figure 3. For example,
the two plasmids comprising Scheme 1 contained back-up
markers conferring resistance to ampicillin and chlorampheni-
col. After cotransforming pTara and pCS1 into competent cells,
the outgrowth was split and plated either onto LB agar with
ampicillin and chloramphenicol or onto LB agar with just
kanamycin. When compared to plating onto the back-up
resistance markers, the transformation eﬃciency of Scheme 1
was just 13% (Figure 3A).
Similar results were obtained when examining Schemes 2 and
3, as shown in Figure 3B and C, respectively. The relative
transformation eﬃciency of Scheme 2 was just 3%. For Scheme
Figure 2. The three-plasmid system. (A) Scheme 3: Circuit design for stable maintenance of three plasmids. The two halves of the Neo gene from
scheme three are placed under the control of the PT7/lac promoter. Therefore, the plasmid containing T7RNAP from Scheme 1 is also required for
resistance to kanamycin. (B) Cells streaked onto plates containing only kanamycin shows that only those cells containing all three plasmids are
capable of growing. (C) Cells grown in liquid LB with kanamycin only proliferate when all three plasmids are present. No growth was ever seen in
either liquid or on plates when one, two or all three plasmids were absent. Photographs in (B) and (C) are representative samples of at least three
experiments. Error bars in (C) are the standard deviations from three separate cultures.
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3, the three back-up resistance genes conferred resistance to
ampicillin, tetracycline and spectinomycin. Co-transformation
of the three plasmids in Scheme 3 onto plates containing all 3
back-up markers was possible, but we obtained no colonies
when we plated onto kanamycin only. However, when we
added 1 mM IPTG, we found robust growth, with a relative
transformation eﬃciency of approximately 25%. Note that
while IPTG, which helps to induce the PT7/lac promoter, is
necessary to transform Scheme 3 directly onto kanamycin, it is
not necessary for growth in liquid culture. In fact, cells
containing Scheme 3 grown in liquid culture with kanamycin
grow decidedly better in the absence of IPTG, as shown in
Figure 4. Similar results were obtained with Scheme 1 in liquid
culture.
Though the rates for transforming these circuits directly onto
kanamycin was signiﬁcantly lower than onto their back-up
markers, it should be noted that when concentrations of
plasmids are similar to that which can be obtained with a
standard puriﬁcation method, the number of colonies of
DH10B electrocompetent transformants on kanamycin is so
great that it is nearly impossible to distinguish single colonies.
This indicates that removal of the individual resistance genes
prior to ﬁnal assembly would be possible.
As the growth rate was aﬀected by the levels of transcription
by T7 RNAP (as induced by IPTG), we hypothesized that
putting T7RNAP on a plasmid with an origin of replication that
confers a lower copy might result in increased cell growth.
pTara contains a p15a origin of replication, which confers a
copy number of approximately 15 per cell.16 We therefore
placed the promoter and gene driving expression of T7RNAP
into a vector that has a pSC101 origin, which confers a copy
number of approximately 5 per cell.15 This new scheme we
called Scheme 1LC (Low Copy). We then measured the
growth rates of cells containing either Scheme 1 or Scheme
1LC in the presence or absence of 1 mM IPTG, as shown in
Figure 5.
For uninduced cells, there was no diﬀerence in growth rate
(Figure 5 red and black curves). However, Scheme 1LC
signiﬁcantly outgrew Scheme 1 when we induced the cells with
1 mM IPTG (Figure 5 green and blue curves). Therefore, while
some increase in growth rate is attainable when T7RNAP is
expressed oﬀ of a low copy number in the presence of IPTG,
growth was best in its absence.
We next wanted to test whether or not each scheme could be
used to stably maintain the plasmids within the hosts during
long-term serial dilution experiments. To do this, we performed
serial dilution experiments on each scheme in liquid LB
containing only kanamycin (see Methods section). Each
morning the overnight cultures were used to seed the next
round, and then plasmid DNA was extracted, digested and run
through an agarose gel to determine the presence or absence of
each plasmid. The results of these experiments are shown in
Figure 6.
We found that each scheme could be stably maintained with
only kanamycin during serial dilution for many weeks. For
instance, Scheme 1 maintained both pTara and pCS1 for more
than a month (Figure 6A, left and right). This maintenance was
Figure 3. Transformation eﬃciency of the multiplasmid schemes. (A)
Relative transformation eﬃciency of Scheme 1. When cells were plated
directly onto kanamycin plates (right), the eﬃciency was roughly 13%
of the eﬃciency when plated onto dual-selection plates (left). The
dual-selection plate contained ampicillin and chloramphenicol, the
back-up resistance markers for the two plasmids in Scheme 1. (B) The
transformation eﬃciency of Scheme 2 when plated onto kanamycin
plates (right) was 3% of that when plated onto dual selection plates
(left). (C) Relative transformation eﬃciency of Scheme 3. Here, we
found no colonies when plated directly onto kanamycin plates.
However, when 1 mM IPTG (which induces the PT7/lac promoter) was
added to the kanamycin plates, the relative eﬃciency was 25%.
Figure 4. Growth of Scheme 3 in liquid culture. The growth of
Scheme 3 in liquid culture containing kanamycin is signiﬁcantly better
in the absence of IPTG (black lines, squares) than in the presence of 1
mM IPTG (red line, circles).
Figure 5. The eﬀect of copy number on growth. The growth of
Scheme 1 and Scheme 1LC are nearly identical in the absence of IPTG
(red and black curves, respectively). The presence of 1 mM IPTG
drastically reduces the growth of cells containing Scheme 1 (blue
curve). Scheme 1LC does better in the presence of IPTG (green
curve) but still worse than either in the absence of IPTG.
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not just a remnant of nonselected plasmid maintenance, as
cultures grown in the presence of only chloramphenicol (which
selects for pTara and not pCS1) eventually lose pCS1 (Figure
6A, middle). In the split NptII system, Scheme 2, both plasmids
persisted during serial dilution in the presence of only
kanamycin for well over a month, as shown in Figure 6B. For
both Schemes 1 and 2, six serial dilution experiments yielded
identical results.
The maintenance of Scheme 3 also lasted for at least 14 days,
and sometimes for at least 30 days, in the presence of
kanamycin (Figure 6C). However, in some trials we saw the
emergence of faint bands in the agarose gels (Figure 6C, red
circle), usually around day 14. We were unable to suﬃciently
identify these bands and therefore do not know what they are.
However, it should be noted that the new bands remained faint
and the bands corresponding to the three plasmids that make
up Scheme 3 always persisted for at least 30 days throughout
each of the six serial dilution experiments performed.
There are many reasons to avoid using multiple antibiotics
when implementing large-scale synthetic gene circuits in
bacteria, from reducing stress and metabolic load on cells to
decreasing the cost of growth media. Here, we showed that
stable maintenance of multiple plasmids need not require
multiple antibiotics. The systems we examined are simple to
use, in that they can be directly transformed into any
competent cell strain that lacks kanamycin resistance. This
means that the removal of backup resistance markers is possible
after the subcloning of each plasmid in the system is complete.
Furthermore, the long-term growth of cells in liquid culture is
also possible, as the Schemes we examined maintained their
plasmids in the presence of kanamycin for many weeks. In fact,
we never saw cultures drop any plasmid in either of the two-
plasmid Schemes.
Perhaps the real utility of these Schemes is their possible use
in creating antibiotic-free systems for multiple plasmid
maintenance. This might be done by combining one of the
Schemes examined above with one of the currently existing
methods that are used to generate antibiotic-free maintenance
of single plasmids. For instance, if the neo gene in Scheme 1
were replaced with an essential chromosomal gene, then the
two plasmids would be required for cellular growth in an
appropriate knockout strain. Similar schemes for maintaining
three plasmids without antibiotics are also conceivable.
■ METHODS
Plasmid Construction. pTara was obtained from Dr.
Kathleen Matthews.27 pDimN2a and pDimC8b were obtained
from Dr. Marc Ostermeier and originally named pDIM-N2-
Neo[1-59]N58S and pDIM-C8-Neo[59-264]R177S,V198E,
respectively.19 We used shortened names for brevity. pCS1
was made by PCR amplifying the neo gene from a pET28
vector and then ligating it back into pET28 using the sites NcoI
and BamHI to place it under control of the T7 promoter. The
resulting T7-Neo cassette was then PCR ampliﬁed and ligated
into pBR3225 in the place of the Tet resistance gene using
circular polymerase extension cloning (CPEC).20 pCS4 was
made by PCR amplifying the neo-α gene from pDIMN2 and
ligating into pET28 using the sites NcoI and BamHI. The
resulting T7- neo-α cassette, along with lacI, was then PCR
ampliﬁed and added into pACYC1776 in place of the
kanamycin resistance gene using CPEC. pCS5 was made by
PCR amplifying the neo-β gene from pDIMN2 and ligating into
pET28 using the sites NcoI and BamHI. The T7- neo-β cassette
was then PCR ampliﬁed and ligated into pBR322 in the place of
the bla gene using the sites AseI and EcoRI. pCS6 was made by
PCR amplifying the genes encoding T7RNAP and AraC from
pTara and inserting the resulting fragment into pZS418 in the
place of lacI and tetR using CPEC.
Plasmid and Cell Maintenance. Cells were grown in
standard liquid LB or on LB agar plates. The antibiotics were
used at concentrations of 100 μg/mL for ampicillin, 50 μg/mL
for kanamycin, 50 μg/mL for chloramphenicol, 50 μg/mL for
spectinomycin, and 20 μg/mL for tetracycline. IPTG was used
at a concentration of 1 mM. Note that while the gene encoding
T7RNAP in Schemes 1 and 3 is driven by the arabinose-
inducible PBAD promoter, we found that the basal expression
level in the absence of arabinose produced enough T7RNAP
for the circuits to function.
Testing Cell Growth in Culture. Five milliliters of liquid
LB cultures containing appropriate antibiotics and inducers
were inoculated with 50 μL of DH10B cells grown overnight in
LB. These cells had been previously transformed with diﬀerent
plasmids. Growth was measured by transferring 100 μL of
culture to a 96 well plate and taking OD600 measurements using
a TECAN Inﬁnite M1000 plate reader. Measurements were
taken every hour for 6 h, and again at 24 h after inoculation.
Cultures were grown in a 37 °C incubator with shaking.
Testing Circuit Transformation Eﬃciency. DH10B
electrocompetent cells were transformed with 1 μL of DNA
containing plasmids comprising the three diﬀerent gene
circuits. The outgrowth of these cells (≈400 μL) was split,
with 200 μL plated on LB agar plates containing kanamycin,
and 200 μL plated on plates containing antibiotics that select
separately for each plasmid in the circuit. For the circuit
Figure 6. Long-term stability during serial dilution experiment. (A)
Image of an agarose gel containing digested plasmid DNA from one
serial dilution experiment. pTara and pCS1 were both stably
maintained in the presence of only kanamycin. The bands that were
present at day 0 (left) were still present at day 34 after continuous
selection with kanamycin (kan). When chloramphenicol (chlor) was
used to select only for pTara and not for pCS1, pCS1 was lost. (B)
Scheme 2 was maintained in the presence of kanamycin for at least 36
days. (C) Two separate serial dilution experiments with Scheme 3. In
the experiment on the left, Scheme 3 was maintained in the presence
of kanamycin for 30 days. In the right experiment, the plasmids
comprising Scheme 3 are still present in the culture, but an unknown
faint band appeared (red circle) after 2 weeks.
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selecting for three plasmids, the split outgrowth was plated on
kanamycin and kanamycin + 1 mM IPTG plates, while 200 μL
from another transformation was plated on spectinomycin +
tetracycline + ampicillin plates. Cells were grown overnight at
37 °C before counting colonies.
Testing Viability of Individual Plasmids. Every plasmid
combination, including single plasmids of the dual plasmid
systems, and combinations of two plasmids of the three plasmid
system were transformed into DH10B cells and plated on LB
agar plates containing antibiotics selecting for the individual
plasmids. Colonies from these plates were picked into liquid LB
containing the same antibiotics and grown overnight. These
cultures were passed into liquid LB with kanamycin and
streaked on LB agar plates with kanamycin.
Serial Dilution Experiments. Plasmids were transformed
into DH10B cells and plated on LB agar plates selecting for the
individual antibiotic markers for each plasmid. Single colonies
were picked into 3 mL of liquid LB cultures containing
individually selecting antibiotics and grown overnight in a
shaking incubator at 37 °C and 200 rpm. A 1:600 dilution was
created by passing 5 μL of the overnight culture into 3 mL of
liquid LB with kanamycin. They were passed into new media in
this manner every 24 h for the duration of the experiments.
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